Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer’s disease

@article{Dickerson2005NeuroimagingBF,
  title={Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer’s disease},
  author={Bradford C. Dickerson and Reisa A. Sperling},
  journal={NeuroRX},
  year={2005},
  volume={2},
  pages={348-360}
}
The pathophysiologic process leading to neurodegeneration in Alzheimer’s disease (AD) is thought to begin long before clinical symptoms develop. Existing therapeutics for AD improve symptoms, but increasing efforts are being directed toward the development of therapies to impede the pathologic progression of the disease. Although these medications must ultimately demonstrate efficacy in slowing clinical decline, there is a critical need for biomarkers that will indicate whether a candidate… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 55 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 124 references

Automatically parcellating the human cerebral cortex.

Cerebral cortex • 2004
View 4 Excerpts
Highly Influenced

Impairment of neocortical metabolism predicts progression in Alzheimer's disease.

Dementia and geriatric cognitive disorders • 1999
View 4 Excerpts
Highly Influenced

Positron emission tomography and single-photon emission computed tomography in central nervous system drug development

DJ Brooks
NeuroRx 2:226–236, • 2005
View 1 Excerpt

Similar Papers

Loading similar papers…